Company news

Dianthus Therapeutics, Inc. news in 2026

Dianthus Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 2026 Financial Results

November 4, 2026

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 2, 2026

Dianthus Therapeutics to Participate in Five Investor Conferences During November

November 2, 2026

Dianthus Therapeutics Recognized Among Fortune’s 2026 Best Workplaces In BioPharma

October 13, 2026

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 1, 2026

Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting

September 29, 2026

Dianthus Therapeutics to Participate in Three Investor Conferences During September

September 1, 2026

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results

August 4, 2026

Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

August 3, 2026

Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)

July 2, 2026

Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis

June 29, 2026

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)

June 3, 2026

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 2, 2026

Dianthus Therapeutics to Participate in Two Investor Conferences

May 26, 2026

LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis

May 5, 2026

Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

March 12, 2026

Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering

March 9, 2026

Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering

March 8, 2026

Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results

March 8, 2026

Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

March 8, 2026

Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

March 7, 2026

Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference

February 23, 2026

Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

February 4, 2026

Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference

January 4, 2026

Decks in 2026